JP2002531415A - ペプチドベースのインフルエンザ用ワクチン - Google Patents

ペプチドベースのインフルエンザ用ワクチン

Info

Publication number
JP2002531415A
JP2002531415A JP2000584919A JP2000584919A JP2002531415A JP 2002531415 A JP2002531415 A JP 2002531415A JP 2000584919 A JP2000584919 A JP 2000584919A JP 2000584919 A JP2000584919 A JP 2000584919A JP 2002531415 A JP2002531415 A JP 2002531415A
Authority
JP
Japan
Prior art keywords
epitope
human
influenza
epitopes
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000584919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531415A5 (cg-RX-API-DMAC7.html
Inventor
アルノン、ルース
− イエディディア、タマル ベン
レビイ、ラファエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of JP2002531415A publication Critical patent/JP2002531415A/ja
Publication of JP2002531415A5 publication Critical patent/JP2002531415A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2000584919A 1998-11-30 1999-11-28 ペプチドベースのインフルエンザ用ワクチン Pending JP2002531415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12733198A IL127331A0 (en) 1998-11-30 1998-11-30 Peptide-based vaccine for influenza
IL127331 1998-11-30
PCT/IL1999/000640 WO2000032228A2 (en) 1998-11-30 1999-11-28 Peptide-based vaccine for influenza

Publications (2)

Publication Number Publication Date
JP2002531415A true JP2002531415A (ja) 2002-09-24
JP2002531415A5 JP2002531415A5 (cg-RX-API-DMAC7.html) 2006-08-31

Family

ID=11072200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000584919A Pending JP2002531415A (ja) 1998-11-30 1999-11-28 ペプチドベースのインフルエンザ用ワクチン

Country Status (15)

Country Link
US (3) US6740325B1 (cg-RX-API-DMAC7.html)
EP (2) EP1135159A2 (cg-RX-API-DMAC7.html)
JP (1) JP2002531415A (cg-RX-API-DMAC7.html)
KR (1) KR100703571B1 (cg-RX-API-DMAC7.html)
AT (1) ATE556719T1 (cg-RX-API-DMAC7.html)
AU (1) AU766883B2 (cg-RX-API-DMAC7.html)
BR (1) BR9915811A (cg-RX-API-DMAC7.html)
CA (1) CA2352454C (cg-RX-API-DMAC7.html)
DK (1) DK2204187T3 (cg-RX-API-DMAC7.html)
ES (1) ES2389611T3 (cg-RX-API-DMAC7.html)
HK (1) HK1040620A1 (cg-RX-API-DMAC7.html)
IL (3) IL127331A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ511918A (cg-RX-API-DMAC7.html)
PT (1) PT2204187E (cg-RX-API-DMAC7.html)
WO (1) WO2000032228A2 (cg-RX-API-DMAC7.html)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2762161A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for mucosal administration
EP2762159A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
EP2762154A2 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal administration
EP2762156A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
EP2762152A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
EP2762153A2 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for mucosal administration
EP2762157A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
EP2762158A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for transdermal administration
EP2762155A2 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine Composition
EP2762160A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
JP2016155829A (ja) * 2007-08-31 2016-09-01 アルティミューン ユーケー リミテッド インフルエンザ抗原送達用のベクターおよび構築体
US10471141B2 (en) 2014-09-03 2019-11-12 Nitto Denko Corporation Bisphosphonate-containing vaccine pharmaceutical composition for humoral immunity
US10925936B2 (en) 2014-09-03 2021-02-23 Nitto Denko Corporation Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates
US11278616B2 (en) 2015-08-06 2022-03-22 Nitto Denko Corporation Immunity induction promoting composition, and vaccine pharmaceutical composition

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
WO2002026252A1 (en) * 2000-08-10 2002-04-04 Tsinghua University A vaccine for influenza virus and its preparation
FI20031536A0 (fi) * 2003-10-20 2003-10-20 Biotie Therapies Oyj Korkean affiniteetin ligandit influenssavirukselle ja menetelmät niiden valmistamiseen
PL1692265T3 (pl) 2003-11-04 2011-12-30 The Administrators Of The Tulane Educational Fund Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
WO2006074303A2 (en) * 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
AR052195A1 (es) 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso
FI20060200A0 (fi) * 2005-04-20 2006-02-27 Glykos Finland Oy Menetelmä ihmisen influenssaviruksen sialihahappositoumisspesifisyyden analysoimiseksi
KR20080027777A (ko) * 2005-06-01 2008-03-28 배리에이션 바이오테크놀로지스 아이엔씨. 펩티드­기초 인플루엔자 백신 제제
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US7468187B2 (en) * 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
US20090169576A1 (en) * 2005-10-26 2009-07-02 Roberto Crea Influenza combinatorial antigen vaccine
AU2006311752A1 (en) * 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center CD40 ligand fusion protein vaccine
DK1968632T3 (da) 2005-12-06 2012-07-16 Yeda Res & Dev Forbedret influenzavaccine
PL2478916T3 (pl) * 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
ES2555544T3 (es) * 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
US20110129438A1 (en) * 2006-06-28 2011-06-02 James Robert Swartz Immunogenic protein constructs
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
WO2008112218A2 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
WO2009016639A2 (en) 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
CA2721800A1 (en) 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
JP2011519834A (ja) * 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
WO2009135152A2 (en) 2008-05-02 2009-11-05 University Of Rochester Arrayed detector system for measurement of influenza immune response
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
CA2840982C (en) 2011-07-06 2022-06-07 Vira BITKO Human respiratory syncytial virus vaccine
JP6205360B2 (ja) 2011-08-22 2017-09-27 ナノバイオ コーポレーション 単純ヘルペスウイルスのナノエマルジョンワクチン
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
RU2531235C2 (ru) * 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
CN103901202B (zh) * 2014-04-04 2015-08-12 中国人民解放军成都军区疾病预防控制中心 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法
BR112019013402A2 (pt) * 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza
WO2026101847A1 (en) 2024-11-05 2026-05-15 Bluewillow Biologics, Inc. Methods of influenza vaccination and compositions for the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
WO1997044667A2 (fr) * 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016155829A (ja) * 2007-08-31 2016-09-01 アルティミューン ユーケー リミテッド インフルエンザ抗原送達用のベクターおよび構築体
KR20140099829A (ko) 2013-02-05 2014-08-13 닛토덴코 가부시키가이샤 점막 투여용 wt1 펩티드 암 백신 조성물
JP2014169283A (ja) * 2013-02-05 2014-09-18 Nitto Denko Corp 粘膜投与用ワクチン組成物
EP2762156A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
EP2762152A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
EP2762153A2 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for mucosal administration
EP2762157A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
EP2762158A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for transdermal administration
EP2762155A2 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine Composition
EP2762160A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
EP2762159A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
EP2762154A2 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal administration
KR20140100421A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 wt1 펩티드 암 백신 테이프제
EP2762161A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for mucosal administration
US10071051B2 (en) 2013-02-05 2018-09-11 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
US10076491B2 (en) 2013-02-05 2018-09-18 Nitto Denko Corporation Vaccine composition
US10195258B2 (en) 2013-02-05 2019-02-05 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
US10206985B2 (en) 2013-02-05 2019-02-19 Nitto Denko Corporation WT1 peptide cancer vaccine composition for mucosal administration
US10449144B2 (en) 2013-02-05 2019-10-22 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
EP3662927A2 (en) 2013-02-05 2020-06-10 Nitto Denko Corporation Vaccine composition
US10471141B2 (en) 2014-09-03 2019-11-12 Nitto Denko Corporation Bisphosphonate-containing vaccine pharmaceutical composition for humoral immunity
US10925936B2 (en) 2014-09-03 2021-02-23 Nitto Denko Corporation Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates
US11278616B2 (en) 2015-08-06 2022-03-22 Nitto Denko Corporation Immunity induction promoting composition, and vaccine pharmaceutical composition

Also Published As

Publication number Publication date
IL143367A (en) 2006-09-05
HK1040620A1 (zh) 2002-06-21
HK1145448A1 (en) 2011-04-21
KR20010089512A (ko) 2001-10-06
ATE556719T1 (de) 2012-05-15
NZ511918A (en) 2003-08-29
AU1406600A (en) 2000-06-19
PT2204187E (pt) 2012-08-10
US7514086B2 (en) 2009-04-07
AU766883B2 (en) 2003-10-23
CA2352454A1 (en) 2000-06-08
EP2204187B1 (en) 2012-05-09
WO2000032228A3 (en) 2000-10-05
EP2204187A1 (en) 2010-07-07
US20050002954A1 (en) 2005-01-06
US20070122424A1 (en) 2007-05-31
IL143367A0 (en) 2002-04-21
US6740325B1 (en) 2004-05-25
CA2352454C (en) 2013-02-05
BR9915811A (pt) 2001-08-21
IL127331A0 (en) 1999-09-22
US7192595B2 (en) 2007-03-20
EP1135159A2 (en) 2001-09-26
KR100703571B1 (ko) 2007-04-05
ES2389611T3 (es) 2012-10-29
DK2204187T3 (da) 2012-08-20
WO2000032228A2 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
US7192595B2 (en) Peptide-based vaccine for influenza
AU770923B2 (en) Inactivated influenza virus vaccine for nasal or oral administration
Eliasson et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine
Lunn et al. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene
KR100186783B1 (ko) 적혈구와 표면-결합된 항원을 포함하는 경구용 백신
Jeon et al. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus
US7914797B2 (en) Influenza vaccine
Ben-Yedidia et al. Towards an epitope-based human vaccine for influenza
JPH03502687A (ja) レスピラトリイ・シンシチアル・ウイルス:ワクチンおよび診断法
US5674502A (en) Cross-reactive influenza a immunization
Music et al. Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets
Webster et al. Matrix protein from influenza A virus and its role in cross-protection in mice
US12397050B2 (en) Universal mammalian influenza vaccine
Scheepers et al. Protection of mice against an influenza virus infection by oral vaccination with viral nucleoprotein incorporated into immunostimulating complexes
WO2025092866A1 (zh) 一种多价流感mRNA疫苗
Skea et al. The immunotargeting approach to adjuvant-independent immunization with influenza haemagglutinin
Arnon et al. Synthetic recombinant vaccines against viral agents
MXPA01005398A (en) Peptide-based vaccine for influenza
HK1145448B (en) Human flu vaccine containing four influenza peptides
WO1994022917A1 (en) Cross-reactive influenza a immunization
Laver et al. The Influenza Virus Hemagglutinin: Symposium, Baden near Vienna, March 21–23, 1977
Arnon Development of Synthetic Vaccines
SYNTHETICALLY COMPOSITE SALMONELLA E. COLI, VIBRIO CHOLERAE VACCINE STRAINS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100129